Inborn errors of metabolism:

Indications for STRENSIQ:

Treatment of perinatal/infantile- and juvenile-onset hypophosphatasia.


Not applicable.


See full labeling. Give by SC inj in the abdomen, thigh, or deltoid; rotate inj sites. 6mg/kg per week given as 2mg/kg 3 times weekly or 1mg/kg 6 times weekly. Perinatal/infantile-onset: if ineffective, may increase dose up to 9mg/kg per week given as 3mg/kg 3 times weekly. <40kg: do not use 80mg/0.8mL vial.


Do not administer to areas that are reddened, inflamed, or swollen. Discontinue if severe hypersensitivity reaction occurs; monitor for reoccurrence if decision to re-administer. Perform ophthalmic exams and renal ultrasounds at baseline and periodically during treatment; monitor for ectopic calcifications and changes in vision or renal function. Pregnancy. Nursing mothers.

Pharmacologic Class:

Tissue nonspecific alkaline phosphatase.


May cause erroneous results in lab assays that utilize alkaline phosphatase (ALP)-conjugated test system. Do not rely on serum ALP measurements for clinical decision making due to expected high levels.

Adverse Reactions:

Inj site reactions, lipodystrophy, ectopic calcifications, hypersensitivity reactions.

Generic Availability:


How Supplied:

Single-use vials—1, 12